• Home
  • Politics
  • Health
  • World
  • Business
  • Finance
  • Tech
  • More
    • Sports
    • Entertainment
    • Lifestyle
What's Hot

Trump Announces First Post-Tariff Trade Deal

May 8, 2025

100 Funny Father’s Day Quotes for Hilariously Relatable Humor (and Plenty of Love Too)

May 8, 2025

Top 10 Benefits Of Acupuncture

May 8, 2025
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Thursday, May 8
Patriot Now NewsPatriot Now News
  • Home
  • Politics

    Security video shows brazen sexual assault of California woman by homeless man

    October 24, 2023

    Woman makes disturbing discovery after her boyfriend chases away home intruder who stabbed him

    October 24, 2023

    Poll finds Americans overwhelmingly support Israel’s war on Hamas, but younger Americans defend Hamas

    October 24, 2023

    Off-duty pilot charged with 83 counts of attempted murder after allegedly trying to shut off engines midflight on Alaska Airlines

    October 23, 2023

    Leaked audio of Shelia Jackson Lee abusively cursing staffer

    October 22, 2023
  • Health

    Disparities In Cataract Care Are A Sorry Sight

    October 16, 2023

    Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

    October 16, 2023

    Long-term steroid use should be a last resort

    October 16, 2023

    Rite Aid Files For Bankruptcy With More ‘Underperforming Stores’ To Close

    October 16, 2023

    Who’s Still Dying From Complications Related To Covid-19?

    October 16, 2023
  • World

    New York Democrat Dan Goldman Accuses ‘Conservatives in the South’ of Holding Rallies with ‘Swastikas’

    October 13, 2023

    IDF Ret. Major General Describes Rushing to Save Son, Granddaughter During Hamas Invasion

    October 13, 2023

    Black Lives Matter Group Deletes Tweet Showing Support for Hamas 

    October 13, 2023

    AOC Denounces NYC Rally Cheering Hamas Terrorism: ‘Unacceptable’

    October 13, 2023

    L.A. Prosecutors Call Out Soros-Backed Gascón for Silence on Israel

    October 13, 2023
  • Business

    Trump Announces First Post-Tariff Trade Deal

    May 8, 2025

    Electric Vehicle Sales Nosedive As GOP Takes Buzzsaw To Biden’s Mandate

    May 7, 2025

    Tyson Foods Announces It Will Bend The Knee To Trump Admin’s New Rules

    May 7, 2025

    Federal Reserve Holds Interest Rates Steady Despite Pressure From Trump

    May 7, 2025

    ‘Wait Them Out’: John Kennedy Tells Larry Kudlow One Lie He Suspects China’s Telling US

    May 7, 2025
  • Finance

    Ending China’s De Minimis Exception Brings 3 Benefits for Americans

    April 17, 2025

    The Trump Tariff Shock Should Push Indonesia to Reform Its Economy

    April 17, 2025

    Tariff Talks an Opportunity to Reinvigorate the Japan-US Alliance

    April 17, 2025

    How China’s Companies Are Responding to the US Trade War

    April 16, 2025

    The US Flip-flop Over H20 Chip Restrictions 

    April 16, 2025
  • Tech

    Cruz Confronts Zuckerberg on Pointless Warning for Child Porn Searches

    February 2, 2024

    FTX Abandons Plans to Relaunch Crypto Exchange, Commits to Full Repayment of Customers and Creditors

    February 2, 2024

    Elon Musk Proposes Tesla Reincorporates in Texas After Delaware Judge Voids Pay Package

    February 2, 2024

    Tesla’s Elon Musk Tops Disney’s Bob Iger as Most Overrated Chief Executive

    February 2, 2024

    Mark Zuckerberg’s Wealth Grew $84 Billion in 2023 as Pedophiles Target Children on Facebook, Instagram

    February 2, 2024
  • More
    • Sports
    • Entertainment
    • Lifestyle
Patriot Now NewsPatriot Now News
Home»Health»Donanemab’s Data Look Promising, But It Won’t Lead To An Imminent Change In Medicare’s Severe Restrictions On Coverage Of Alzheimer’s Disease Biologics
Health

Donanemab’s Data Look Promising, But It Won’t Lead To An Imminent Change In Medicare’s Severe Restrictions On Coverage Of Alzheimer’s Disease Biologics

May 5, 2023No Comments5 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Donanemab’s Data Look Promising, But It Won’t Lead To An Imminent Change In Medicare’s Severe Restrictions On Coverage Of Alzheimer’s Disease Biologics
Share
Facebook Twitter LinkedIn Pinterest Email

Scan images of brains of Alzheimer’s Disease patients.

getty

This week, Eli Lilly announced that its beta amyloid-directed monoclonal antibody named donanemab showed in a clinical trial that it can slow progress of Alzheimer’s Disease (AD). The trial included 1,736 patients. Use of donanemab led to a lessening of cognitive and functional decline of 36% compared with placebo. This was measured on the clinical dementia rating (CDR) scale, which is commonly used to diagnose dementia from AD. The sum of boxes of the CDR traces the progression of cognitive and functional impairment in the early stages of AD.

The topline numbers released by Lilly also reveal a risk of brain swelling and hemorrhaging, side effects that may be linked to three deaths in the clinical trial. Similarly, deaths occurred in the clinical trial of another beta amyloid-directed monoclonal antibody, Leqembi (lecanemab), which was granted an accelerated approval by the Food and Drug Administration (FDA) in January of this year.

In April 2022, the Centers for Medicare and Medicaid Services (CMS) issued a National Coverage Determination (NCD) that narrowly restricts reimbursement of biologics in the class of beta amyloid-directed antibodies to those enrolled in a post-marketing randomized controlled clinical trial. At the time of issuance of the NCD, the only approved biologic targeting AD was Aduhelm (aducanumab).

In the NCD’s decision memorandum, CMS indicated it would change course for regularly approved therapeutic agents if they can answer the following question in the affirmative:

“Does the anti-amyloid monoclonal antibody meaningfully improve health outcomes (that is, slow the decline of cognition and function) for patients in broad community practice?”

It’s certainly possible that once lecanemab and donanemab receive regular FDA approval, CMS will deem these two biologics worthy of meeting the reasonable and necessary standard for Medicare reimbursement.

But it’s not probable that the NCD itself will be voided in its entirety. Given that the late-stage clinical trials of each of four monoclonal antibodies have shown strikingly different results,* it’s more likely that a case-by-case approach for determining coverage and conditions of reimbursement for each antibody will be adopted.

With donanemab, 47% of patients remained stable in terms of their cognitive function and ability to perform daily activities during the subsequent year compared with 29% who took the placebo.

But at the same time findings from the trial show that 24% of patients had at least some brain swelling and bleeding, and 6% experienced symptoms like dizziness, headache or fainting.

And so, questions remain, including details on three deaths that may be related to the biologic, and which sub-group(s) of patients stand to benefit most. Lilly intends to present a comprehensive data analysis at a medical conference in Amsterdam this July, as well as in a forthcoming peer-reviewed publication.

Surely, the pharmaceutical industry and patient advocacy groups like the Alzheimer’s Association will push even harder for CMS to reverse its NCD and cover the class of drugs that target beta amyloid plaque. However, CMS is faced with a situation in which two drugs in the class appear to work and two don’t (gantenerumab and Aduhelm). A phase 3 clinical trial of gantenerumab was stopped early because of a lack efficacy, while Aduhelm, despite accelerated approval, didn’t yield statistically significant efficacy. The two that have shown promise provide relatively modest benefits with potentially serious side effects. While certain NCD restrictions could be lifted on a case-by-case basis, rescinding the NCD isn’t probable.

To illustrate how this might play out, let’s take the case of lecanemab. CMS has said it would broaden its coverage of lecanemab “on the same day” the FDA grants a regular approval of the biologic. The date for this decision is July 6th.

Though opinions from experts differ on the matter of how clinical meaningful the lecanemab trial data outcomes are, presumably lecanemab’s regular FDA approval will lead to a loosening of Medicare coverage restrictions. For example, should FDA give the nod to lecanemab in July, CMS will drop the randomized controlled trial precondition, though it could still require the establishment of a patient registry (or multiple registries) as a way to systematically collect post-marketing evidence on lecanemab’s safety and effectiveness in the real world. Furthermore, there would likely be a number of other coverage limitations, including at least some of the ones the Department of Veterans Affairs is imposing.

And what applies to lecanemab will likely apply to donanemab. The process for regular FDA approval of donanemab will be based on an evaluation of the full set of Phase 3 trial data. Submission for such approval won’t happen until this summer at the earliest.

Donanemab’s topline numbers drew immediate comparison to lecanemab, which slowed cognitive decline by 27% on the sum of boxes CDR. However, comparisons are hard to draw between donanemab and lecanemab owing to differences in the patient cohorts. But one difference that is independent of the qualitative discrepancies between the patient cohorts is the fact that lecanemab requires infusions every other week for an indefinite period of time, while donanemab is infused every four weeks, and only until a patient tests negative for amyloid plaque on brain scans. Fewer courses of treatment could make Lilly’s drug cheaper in the long term. But this would depend on donanemab’s pricing, which is unknown at this time.

Until lecanemab and donanemab are granted regular FDA approval it’s very unlikely there will be a change in Medicare’s current severely restrictive coverage policy. Once approved, however, Medicare will be inclined to relax coverage limits. This said, upon approval unfettered access will not be a plausible scenario.

See also  8 Ways Learning Disabilities Affect Your Child’s Mental Health
Alzheimers Biologics Change Coverage data disease Donanemabs imminent Lead Medicares promising Restrictions Severe wont
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Trump’s Tariffs Trigger Turmoil In China As Country’s Economic Tailspin Intensifies Per New Data

May 6, 2025

The US Flip-flop Over H20 Chip Restrictions 

April 16, 2025

‘Is Our Patriotism Tied To Wall Street’: Charles Payne Rips Media For Ignoring Blue Collar Workers In Tariff Coverage

April 3, 2025

‘His Agenda Coming To Life’: Trump Secures Massive Foreign Investment To Build Out US Data Centers

January 7, 2025
Add A Comment

Leave A Reply Cancel Reply

Top Posts

EU Sanctions Envoy Strikes Positive Tone in Astana

November 30, 2023

‘Our Business Is In A Difficult Position: Problem-Ridden Boeing Announces Massive Job Cuts As Worker Strike Continues

October 11, 2024

QuantumScape Stock Is Soaring. Earnings Aren’t Driving the Gains.

July 27, 2023

Former Cowboys WR Dez Bryant goes off on Ja Morant after Grizzlies star gets suspended again for showing gun

May 15, 2023
Don't Miss

Trump Announces First Post-Tariff Trade Deal

Business May 8, 2025

President Donald Trump announced Thursday the U.S. has reached a trade agreement with the U.K.,…

100 Funny Father’s Day Quotes for Hilariously Relatable Humor (and Plenty of Love Too)

May 8, 2025

Top 10 Benefits Of Acupuncture

May 8, 2025

Electric Vehicle Sales Nosedive As GOP Takes Buzzsaw To Biden’s Mandate

May 7, 2025
About
About

This is your World, Tech, Health, Entertainment and Sports website. We provide the latest breaking news straight from the News industry.

We're social. Connect with us:

Facebook Twitter Instagram Pinterest
Categories
  • Business (4,110)
  • Entertainment (4,220)
  • Finance (3,202)
  • Health (1,938)
  • Lifestyle (1,626)
  • Politics (3,084)
  • Sports (4,036)
  • Tech (2,006)
  • Uncategorized (4)
  • World (3,944)
Our Picks

11 Dead After Mexico Bar Set On Fire By Man Removed For Bad Behaviour

July 22, 2023

Actor Tom Sizemore in critical condition after brain aneurysm

February 20, 2023

Record-breaking heat in the summer of 2022 caused more than 61,000 deaths in Europe, study finds

July 10, 2023
Popular Posts

Trump Announces First Post-Tariff Trade Deal

May 8, 2025

100 Funny Father’s Day Quotes for Hilariously Relatable Humor (and Plenty of Love Too)

May 8, 2025

Top 10 Benefits Of Acupuncture

May 8, 2025
© 2025 Patriotnownews.com - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.